Human TNFRSF17 / BCMA / CD269 Protein (His & Fc Tag) (PE conjugated)

概述

产品介绍

Cat No. BCMA-PH1205

库存：现货

Size

点击咨询在线客服

产品介绍

General Information

Expression System:	HEK293 Cells
Preparation:	Recombinant human BCMA/TNFRSF17 (NP_001183.2, extracellular domain, Met 1-Ala 54) are conjugated with PE under optimum conditions, the unreacted PE was removed.
Labeling Rate:	The PE to protein molar ratio is 0.1-1
Formulation:	Aqueous solution containing 0.5% BSA and 0.03%Proclin 300
Concentration:	10 μl/Test, 0.1 mg/ml
Form & Shipping:	Liquid. Shipping at ambient temperature.
Storage:	This reagent is stable for 6 months from date of receipt when stored at 2℃ - 8℃. Protected from prolonged exposure to light. Do not freeze !
Usage：	The 5×10E5 cells are suspended in 50 μL washing buffer (1 X PBS + 1% BSA), add 10 μL TNFRSF17-PE, incubate for 45 min at 4℃ from light, then wash 2 times with wash buffer. Analyze by flow cytometry immediately.

Test results

Flow cytometric analysis of anti-BCMA CAR expression. 293 cells were lentivirally transduced with anti-BCMA CAR. Flow cytometric analysis was performed with PE-conjugated recombinant human BCMA (Cat. No. 10620-H03H-P) . Non-transduced 293 cells were used as a control (left).

Human TNFRSF17 / BCMA / CD269 Protein (His & Fc Tag) (PE conjugated): 别称

BCM; BCMA; CD269; TNFRSF13A

BCMA 背景信息

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

全称

tumor necrosis factor receptor superfamily member 17

参考文献

Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94.
O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8.
Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.